Synthesis of Selectively Mono-N-Arylated Aliphatic Diamines<i>via</i>Iridium-Catalyzed Amine Alkylation
作者:Benoît Blank、Stefan Michlik、Rhett Kempe
DOI:10.1002/adsc.200900548
日期:2009.11
A highly selective phosphorus/nitrogen (P,N) ligand-based iridium catalyst system efficiently catalyzes the reaction of arylamines with unprotected amino alcohols, yielding N-arylated aliphatic diamines in yields of up to 93%. The reaction can be performed with a wide variety of branched and linear amino alcohols in combination with various aminopyridines or substituted anilines.
Synthesis, characterization and biological activity of bis(3-Aryl-1-hexahydropyrimidinyl)methanes. Novel heterocyclic polyamine derivatives
作者:Juan Á Bisceglia、María B. García、Rosana Massa、María L. Magri、Mariana Zani、Gabriel O. Gutkind、Liliana R. Orelli
DOI:10.1002/jhet.5570410113
日期:2004.1
described for the synthesis of bis(3-aryl-1-hexahydropyrimidinyl)methanes 1, by condensation of N-aryl-1,3-propanediarnines 2 with formaldehyde. The reaction mechanism involves N-arylhexahydropyrimidines 3 as intermediates. Such compounds can also be prepared efficiently by a methylene exchange reaction between bis-hexahydropyrimidines 1 and the corresponding diamines 2. The antimicrobial activity of compounds
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.